George Simeon — SEC insider filings
SEC reporting owner CIK 1595117. 37 insider filings on record with FilingPulse; latest filed 2026-10-16.
Transaction summary — filings shown
Covers all 37 filings on record, filed 2020-09-28 to 2026-10-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 26 legs across 11 filings — 12,212,531 shares, $216,673,959 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 10 legs across 4 filings — 1,638,290 shares, $46,711,188 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 103.
- Largest priced transaction: purchase of 960,983 shares @ $52.03 ($49,999,945) in CRISPR Therapeutics AG, filed 2025-07-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Arcellx, Inc. (ACLX) | 10% owner | 2 | 2 legs · 1,666,667 sh · $25,000,005 | 4 legs · 1,012,833 sh · $45,589,317 | 10 |
| CRISPR Therapeutics AG (CRSP) | Director | 9 | 3 legs · 989,812 sh · $51,499,918 | 1 leg · 14,514 sh · $720,373 | 11 |
| Zenas BioPharma, Inc. (ZBIO) | 10% owner | 2 | 5 legs · 2,361,609 sh · $40,399,983 | — | 6 |
| Nkarta, Inc. (NKTX) | Director | 8 | 4 legs · 3,333,333 sh · $39,999,995 | — | 6 |
| ADARx Pharmaceuticals, Inc. (ADRX) | Director, 10% owner | 2 | 3 legs · 1,600,000 sh · $27,200,000 | — | 12 |
| Design Therapeutics, Inc. (DSGN) | Director, 10% owner | 8 | 4 legs · 1,150,000 sh · $12,574,078 | — | 10 |
| Odyssey Therapeutics, Inc. (ODTX) | 10% owner | 1 | 3 legs · 555,555 sh · $9,999,990 | 3 legs · 1,780 sh · $32,040 | 30 |
| Avalyn Pharma Inc. (AVLN) | 10% owner | 1 | 2 legs · 555,555 sh · $9,999,990 | — | 8 |
| eFFECTOR Therapeutics, Inc. (EFTR) | 10% owner | 1 | — | 2 legs · 609,163 sh · $369,457 | — |
| Principia Biopharma Inc. (PRNB) | Director | 1 | — | — | 5 |
+1 more issuer among the filings shown — every filing appears in the table below.
Insider filings — George Simeon
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-16 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 30,000 @ $14 · Sale (S): 14,514 @ $49.63 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2026-09-29 | 4 | ADARx Pharmaceuticals, Inc. (ADRX) | Conversion (C): 3,334,938 · Conversion (C): 1,113,666 · Conversion (C): 512,897 · Purchase (P): 592,593 @ $17 · Conversion (C): 1,538,691 · Purchase (P): 414,814 @ $17 · +9 more | EDGAR |
| 2026-09-24 | 3 | ADARx Pharmaceuticals, Inc. (ADRX) | Holdings only — no transactions reported | EDGAR |
| 2026-06-11 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 37,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Design Therapeutics, Inc. (DSGN) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Odyssey Therapeutics, Inc. (ODTX) jointly with SR ONE CAPITAL MANAGEMENT, LLC | Conversion (C): 474,048 · Conversion (C): 139,366 · Conversion (C): 59,692 · Conversion (C): 61,762 · Conversion (C): 683,817 · Option exercise/expiry (X): 191,541 · +30 more | EDGAR |
| 2026-05-01 | 4 | Avalyn Pharma Inc. (AVLN) jointly with SR ONE CAPITAL MANAGEMENT, LLC | Conversion (C): 1,419,298 · Conversion (C): 489,486 · Purchase (P): 277,778 @ $18 · Conversion (C): 354,824 · Conversion (C): 489,486 · Purchase (P): 277,777 @ $18 · +4 more | EDGAR |
| 2025-10-14 | 4 | Zenas BioPharma, Inc. (ZBIO) jointly with SR ONE CAPITAL MANAGEMENT, LLC | Purchase (P): 63,158 @ $19 · Purchase (P): 63,157 @ $19 | EDGAR |
| 2025-07-17 | 4 | CRISPR Therapeutics AG (CRSP) | Purchase (P): 6,510 @ $52.03 · Purchase (P): 22,319 @ $52.03 · Purchase (P): 960,983 @ $52.03 | EDGAR |
| 2025-06-12 | 4 | Design Therapeutics, Inc. (DSGN) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 46,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2024-09-16 | 4 | Zenas BioPharma, Inc. (ZBIO) jointly with SR ONE CAPITAL MANAGEMENT, LLC | Conversion (C): 1,505,388 · Purchase (P): 441,176 @ $17 · Conversion (C): 501,796 · Purchase (P): 1,352,942 @ $17 · Conversion (C): 669,061 · Purchase (P): 441,176 @ $17 · +3 more | EDGAR |
| 2024-06-17 | 4 | Design Therapeutics, Inc. (DSGN) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Nkarta, Inc. (NKTX) | Purchase (P): 1,548,341 @ $10 · Purchase (P): 451,659 @ $10 | EDGAR |
| 2024-02-27 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 63,177 @ $71.50 · Grant/award (A): 216,578 @ $71.50 · Grant/award (A): 769,196 @ $71.50 | EDGAR |
| 2023-11-29 | 4 | eFFECTOR Therapeutics, Inc. (EFTR) jointly with SR ONE CAPITAL MANAGEMENT, LLC, SR One Capital Fund I Aggregator LP, SR ONE CAPITAL PARTNERS I, LP, SR One Co-Invest I, LLC, SR One Co-Invest I Manager, LLC | Sale (S): 430,578 @ $0.61 · Sale (S): 178,585 @ $0.61 | EDGAR |
| 2023-06-09 | 4 | Nkarta, Inc. (NKTK) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | Design Therapeutics, Inc. (DSGN) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-05-15 | 4 | Arcellx, Inc. (ACLX) jointly with SR ONE CAPITAL MANAGEMENT, LLC, SR One Capital Fund I Aggregator LP, SR ONE CAPITAL PARTNERS I, LP, SR One Co-Invest II, LLC, SR One Co-Invest II Manager, LLC | Sale (S): 631,932 @ $45 · Sale (S): 370,612 @ $45 · Sale (S): 6,485 @ $46.15 · Sale (S): 3,804 @ $46.15 | EDGAR |
| 2022-12-20 | 4 | Design Therapeutics, Inc. (DSGN) | Purchase (P): 500,000 @ $8.28 · Purchase (P): 360,000 @ $8.63 · Purchase (P): 40,000 @ $8.14 | EDGAR |
| 2022-08-17 | 4 | Turning Point Therapeutics, Inc. (TPTX) | Disposition to issuer (D): 2,253,660 @ $76 · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 8,500 (derivative) · Disposition to issuer (D): 8,500 (derivative) | EDGAR |
| 2022-06-16 | 4 | Design Therapeutics, Inc. (DSGN) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-04-29 | 4 | Nkarta, Inc. (NKTX) | Purchase (P): 666,667 @ $15 · Purchase (P): 666,666 @ $15 | EDGAR |
| 2022-02-10 | 4 | Arcellx, Inc. (ACLX) jointly with SR ONE CAPITAL MANAGEMENT, LLC, SR ONE CAPITAL PARTNERS I, LP, SR One Capital Fund I Aggregator LP, SR One Co-Invest II, LLC, SR One Co-Invest II Manager, LLC | Conversion (C): 1,550,309 · Conversion (C): 666,651 · Conversion (C): 533,389 · Conversion (C): 649,795 · Purchase (P): 66,667 @ $15 · Conversion (C): 433,196 · +6 more | EDGAR |
| 2021-06-15 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 16,511 (derivative) @ $0 | EDGAR |
| 2021-06-14 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Turning Point Therapeutics, Inc. (TPTX) | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2021-04-01 | 4 | Design Therapeutics, Inc. (DSGN) | Conversion (C): 4,439,839 · Conversion (C): 936,637 · Purchase (P): 250,000 @ $20 · Conversion (C): 7,236,938 (derivative) @ $0 · Conversion (C): 1,526,718 (derivative) @ $0 | EDGAR |
| 2021-03-29 | 4 | Design Therapeutics, Inc. (DSGN) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2020-09-28 | 4 | Principia Biopharma Inc. (PRNB) | Code (U): 2,982,855 @ $100 · Disposition to issuer (D): 28,623 (derivative) · Disposition to issuer (D): 20,475 (derivative) · Disposition to issuer (D): 10,240 (derivative) · Disposition to issuer (D): 10,240 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1595117 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs